• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

PKI-402

Product ID P4132
Cas No. 1173204-81-3
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $140.60 In stock
5 mg $413.30 Please Inquire
10 mg $661.50 Please Inquire
Bulk Quote
Add to Wishlist

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

PKI-402 is an inhibitor of PI3K that is somewhat selective for p110α; it also inhibits mTORC1/2. PKI-402 exhibits anticancer chemotherapeutic activity, inhibiting cell proliferation in vitro and suppressing tumor growth induced by a variety of cancer cells in vitro, such as breast cancer, glioma, and pancreatic cancer.

Product Info

Cas No.

1173204-81-3

Purity

≥98%

Formula

C29H34N10O3

Formula Wt.

570.65

IUPAC Name

1-[4-(3-ethyl-7-morpholin-4-yltriazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-[4-(4-methylpiperazine-1-carbonyl)phenyl]urea

Solubility

DMSO 0.4 mg/mL (0.7 mM) Water Insoluble Ethanol Insoluble

Appearance

Off-white Powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

P4132 MSDS PDF

Info Sheet

P4132 Info Sheet PDF

Brochures

PI3K-Akt-mTORC Pathway Booklet

References

Mallon R, Hollander I, Feldberg L, et al. Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor. Mol Cancer Ther. 2010 Apr;9(4):976-84. PMID: 20371716.

Dehnhardt CM, Venkatesan AM, Delos Santos E, et al. Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402. J Med Chem. 2010 Jan 28;53(2):798-810. PMID: 19968288.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only